Last A$0.12 AUD
Change Today +0.005 / 4.55%
Volume 240.4K
NRT On Other Exchanges
Symbol
Exchange
NASDAQ CM
OTC US
Frankfurt
Stuttgart
As of 12:10 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

novogen ltd (NRT) Snapshot

Open
A$0.11
Previous Close
A$0.11
Day High
A$0.12
Day Low
A$0.11
52 Week High
12/17/14 - A$0.27
52 Week Low
11/19/14 - A$0.08
Market Cap
28.4M
Average Volume 10 Days
2.0M
EPS TTM
A$-0.05
Shares Outstanding
246.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVOGEN LTD (NRT)

Related News

No related news articles were found.

novogen ltd (NRT) Related Businessweek News

No Related Businessweek News Found

novogen ltd (NRT) Details

Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which include super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). Its SBPs technology platform offers drug candidates, which include Cantrixil, an intra-peritoneal product intended for the treatment of abdominal cancers, such as ovarian and pancreatic cancer; Trilexium that is intended for the treatment of neural cancers, including glioblastoma and neuroblastoma; and Trx-7 for the treatment of prostate cancer. The company’s ATMs technology platform targets the cytoskeleton of the cancer cell. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Founded in 1994

novogen ltd (NRT) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: A$332.8K
Company Secretary
Total Annual Compensation: A$57.5K
Vice-President of Drug Discovery, Manufacture...
Total Annual Compensation: A$279.0K
Director of ATM Program
Total Annual Compensation: A$52.5K
Chief Scientific Officer
Total Annual Compensation: A$200.0K
Compensation as of Fiscal Year 2014.

novogen ltd (NRT) Key Developments

Novogen Announces Important Discovery in Regenerative Medicine Program

Novogen Limited announced an important discovery in its regenerative medicine program that has delivered a key proof-of-concept step forward in the quest to develop drugs capable of stimulating the function of brain tissue stem cells. Regenerative medicine is concerned with repairing or replacing tissue lost due to age, disease, damage or congenital defects. In the case of the brain, damage associated with stroke, head trauma or neurodegenerative disease represents a very significant unmet clinical need for such therapies. Novogen scientists now in an important scientific breakthrough have identified a family of compounds with an ability to promote the growth and activity of normal brain stem cells. The dominant approach being taken to brain regeneration is the introduction of tissue stem cells that have been cultured outside of the body. However, delivery of these cells through the skull is very invasive and, so far, these cells seem to be susceptible to the same constraints that limit the resident stem cell population. Novogen adopted the alternative approach of seeking drugs that would promote the migration of stem cells to the site of injury, seek to retain those stem cells at the damaged site, and then promote their regenerative capacities. This offered the potential of a non-invasive, well-tolerated, medicinal approach to a widespread problem.

Novogen Confirms TRXE-009 as a New Potential Treatment for Melanoma

Novogen Limited announced that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma. The company believes this is an important breakthrough discovery for two reasons. The first is that it confirms that TRXE-009 is an important new potential treatment for melanoma, including for the treatment of secondary brain cancers due to melanoma, for which there currently are no effective therapies. The second is that it offers evidence for the first time of an hypothesized link between brain cancer and melanoma.

Novogen Ltd Provides Progress Update on Clinical Study of Cantrixil

Novogen Ltd. has developed a first-in-class experimental chemotherapeutic known as Cantrixil, and is due to enter a first-in-man clinical study in 2015. Cantrixil is a unique development in chemotherapy, being the first cytotoxic chemotherapy to be developed specifically for injection into the body's cavities. The peritoneal and pleural cavities are involved in a large proportion of cancers, and yet the vast majority of chemotherapies continue to be administered in a way that delivers chemotherapies to the cancer via the bloodstream. Delivering the drug directly into the cavity where the cancer is spreading ensures cancer cells are exposed to levels of drug some hundreds of times greater than via the blood. Cantrixil has been developed jointly by Novogen and Yale University and is owned by their joint-venture company, CanTx Inc. Cantrixil is a construct of active drug candidate, TRXE-002, in a cyclodextrin shell. On injection into the cavity, the shell dissolves to release the active drug. Cantrixil has been designed to be non-irritant and to not be dose-limiting due to side-effects. TRXE-002 is the first drug candidate to emerge from the Novogen super-benzopyran drug platform that for the first time kills all forms of cancer cells through a common mechanism. The platform does not rely on a targeted therapeutic approach of identifying a cancer stem cell market, a strategy that carries the risk of the cancer cell developing detours around the blocked target. Cantrixil is set to come into the clinic in Australian hospitals in the first instance, followed by US centres. The Phase 1 study will be enrolling patients with a variety of cancers that either have arisen in the abdomen or have metastasised there and which have become unresponsive to therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRT:AU A$0.12 AUD +0.005

NRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRT.
View Industry Companies
 

Industry Analysis

NRT

Industry Average

Valuation NRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 37.9x
Price/Book 10.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 43.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOGEN LTD, please visit www.novogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.